ÐÏࡱá>þÿ ,.þÿÿÿ+ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿì¥Á€ ð¿]bjbj´V´V 4Ö<Ö<] ÿÿÿÿÿÿ·¨¨ëëëëëÿÿÿÿÿÿÿÿ ÿgŠúúúæèèèèèè$ñ¢“Z ëúúúúú ëëÛ!®®®úRëëæ®úæ®®®ÿÿÿÿ€‘t¬t†ËÿL"®Ò70g®ín@í®íë®$úú®úúúúú  ®úúúgúúúúÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿíúúúúúúúúú¨ ±: CLINICAL PHARMACOLOGY (January Start) (MSc/PgDip with a view to transfer to MSc/PgDip/PgCert) 57B201BT/61B201BT/61B201X5/62B201VZ Qualifications for entry: A degree or equivalent qualification, at the prescribed standard in Medicine, Pharmacology, Pharmacy or a relevant Science subject (e.g. Biochemistry, Biology, Biomedical Science). Duration: 12 months full-time or 24 months part-time (MSc); 9 months full-time (PgDip) Aim: To equip students for careers developing and expanding current knowledge of drugs. To achieve this the programme will provide a multi-disciplinary approach to the study of drug discovery and development; mechanisms of drug action; preclinical and clinical trials; and regulatory affairs. Content: The programme of taught courses will comprise lectures, tutorials, practical classes and directed self-learning. The curriculum includes biochemical and molecular aspects of drug action; drug transport, metabolism and excretion; toxicology; pharmacokinetics; statistics; computing studies; industrial aspects of drug development; therapeutics; therapeutic drug monitoring; the influence of disease on drug handling; drug-drug interactions; the design and conduct of volunteer and clinical trials; monitoring drug safety. Candidates shall be required to attend the following designated programme of courses: Stage 1 - Second Half-Session GS 55M1 Generic Skills (0 credit points) MT 5501 Pharmacovigilance (5 credit points) MT 5502 Drug Development to Evidence Based Medicine (20 credit points) MT 5510 Introduction to Research Methods (10 credit points) BT 5502 Biologic Therapies (25 credit points) Stage 2 – April to September MT58XX Research Project (60 credit points) Stage 3 - First Half-Session MT 5003 Drug Metabolism and Toxicology (15 credit points) MT 5004 Therapeutics (10 credit points) MT 5014 Molecular pharmacology, drug development and discovery (20 credit points) PU 5005 Applied Statistics (10 credit points) MB 5009 Molecular Biology Basics (10 credit points) Assessment: By practical work, by written essays and by oral presentations, or by a combination of these, as prescribed for each course. The project and dissertation will be assessed and there will usually be an oral examination on completion of the programme. Candidates must pass all courses at an appropriate standard for the award of the MSc degree. �©` j ¸ ¹ ¿ á ê O l wÝõö÷\]øïøïøæïøïøÝøÝøÒøïøÎhelíhZR�h/FñOJQJh/Fñ>*OJQJh/Fñ5�OJQJh/Fñ6�OJQJh/FñOJQJiŽ�_ ` ¸ ¹ à á ÷ ø N O m n — Ä HvóçÛξÎÎÎÎξÎÎÎα±±±± Æ„Àd2ÿgd/Fñ$ Æ0d2ÿa$gd/Fñ Æ0d2ÿgd/Fñ  Æ9r d2ÿgd/Fñ  ÆD%Âdðgd/Fñ  Æ6$Âdðgd/Fñvw”•ÀÁÞßA“Áõö÷\]òããããÖÇòòòòòãÖÖÅ Æ 0*Àd2ÿgd/Fñ Æ0d2ÿgd/Fñ Æ 0„Àd2ÿgd/Fñ Æ„Àd2ÿgd/Fñ21�h:pelí°‚. °ÆA!° "° #� $� %°°Ä°Ä �Äj ˜žžžžžžž666666666vvvvvvvvv66666>666666666666666666666666666¨6666666666¸666666666666hH66666666666666666666666666666666666666666666666666666666666666666°62ÀÐàð 0@P`p€�ÀÐàð2(Øè 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�8XøV~ OJPJQJ_HmH nH sH tH R`ñÿR /FñNormal$a$$CJOJPJQJ^J_HmH sH tH >`> /Fñ Heading 3$d8ÿ@&5�DA òÿ¡D Default Paragraph FontRióÿ³R 0 Table Normalö4Ö l4Öaö (k ôÿÁ( 0No List Pþ/¢ñP /FñHeading 3 Char5CJOJPJQJ^JaJ4`4 /FñHeader  Æ9r Fþ/¢F /Fñ Header CharCJOJPJQJ^JaJPK!‚мú[Content_Types].xml¬‘ËjÃ0E÷…þƒÐ¶Ørº(¥ØÎ¢Iw},Òä±-j�„4 Éßwì¸Pº-t#bΙ{U®�ã “óTéU^h…d}㨫ôûî)»×*1Pƒ'¬ô “^××Wåî0)™¦Též9<“l�#¤Ü$yi}�å;À~@‡æ¶(îŒõÄHœñÄÐuù* D× zƒÈ/0ŠÇ° ðûù $€˜ X«Ç3aZ¢ÒÂà,°D0j~è3ß¶Îbãí~i>ƒØÍ3¿\`õ?ê/ç[ج¶Géâ\Ä!ý-ÛRk.“sþÔ»�..—·´aæ¿­?ÿÿPK!¥Ö§çÀ6 _rels/.rels„�ÏjÃ0 ‡ï…½ƒÑ}QÒÃ%v/¥�C/£}á(h"ÛëÛOÇ »„¤ï÷©=þ®‹ùá”ç šªÃâC?Ëháv=¿‚É…¤§%[xp†£{Ûµ_¼PÑ£<Í1¥H¶0•ˆÙO¼R®BdÑÉÒJEÛ4b$§‘q_טžà6LÓõR×7`®�¨Éÿ³Ã0ÌžOÁ¯,åEn7”Liäb¡¨/ãS½�¨eªÔе¸ùÖýÿÿPK!ky–ƒŠtheme/theme/themeManager.xml ÌM à @á}¡w�Ù7c»(Eb²Ë®»öCœAÇ ÒŸÛ×åãƒ7ÎßÕ›K Y,œ ŠeÍ.ˆ·ð|,§¨ÚHÅ,láÇæéxÉ´�ßIÈsQ}#Õ�…­µÝ Öµ+Õ!ï,Ý^¹$j=‹GWèÓ÷)âEë+& 8ýÿÿPK!–µ­â–Ptheme/theme/theme1.xmlìYOoÛ6¿Øw toc'vuŠØ±›-MÄn‡i‰–ØP¢@ÒI}Úã€úa‡Øm‡a[�Ø¥û4Ù:lЯ°GR’ÅX^’6ØŠ­>$ùãûÿ©«×îÇ !)OÚ^ýrÍC$ñy@“°íÝö/­yH*œ˜ñ„´½)‘Þµ�÷ß»Š×UDb‚`}"×qÛ‹”J×—–¤ÃX^æ)I`nÌEŒ¼Šp)øèÆli¹V[]Š1M<”àÈÞ�©OÐP“ô6râ=¯‰’zÀgb Ig…Áu��SÙebÖö€OÀ�†ä¾òÃRÁDÛ«™Ÿ·´qu ¯g‹˜Z°¶´®o~ÙºlAp°lxŠpT0­÷­+[}`j×ëõº½zAϰV–2ÍF­ÞÉi–@öqžv·Ö¬5\|‰þʜ̭N§Óle²X¢dsøµÚjcsÙÁ�Å7çð�Îf·»êà ÈâWçðý+­Õ†‹7 ˆÑä`­ÚïgÔ È˜³íJøÀ×j|†‚h(¢K³óD-еß㢠dXÑ©iJÆØ‡(îâx$(Ö ð:Á¥;ä˹!Í I_ÐTµ½S 1£÷êù÷¯ž?EÇž?øéøáÃã?ZBΪmœ„åU/¿ýìÏÇ£?ž~óòÑÕxYÆÿúÃ'¿üüy5Òg&΋/ŸüöìÉ‹¯>ýý»GðM�Geø�ÆD¢›äíó3Vq%'#q¾ÃÓòŠÍ$”8ÁšKýžŠôÍ)f™w9:ĵàå£ x}rÏx‰‰¢œw¢ØîrÎ:\TZaGó*™y8IÂjæbRÆíc|XÅ»‹Ç¿½I u3KGñnD1÷NIBÒsü€� íîRêØu—ú‚K>Vè.EL+M2¤#'šf‹¶i ~™Vé þvl³{u8«Òz‹ºHÈ Ì*„æ˜ñ:ž(W‘☕ ~«¨JÈÁTøe\O*ðtHG½€HYµæ–}KNßÁP±*ݾ˦±‹ŠTѼ�9/#·øA7ÂqZ…Ð$*c?�¢íqUßån†èwðNºû%Ž»O¯·ièˆ4 =3Ú—Pª� ÓäïÊ1£P�m \\9†øâëÇ‘õ¶âMØ“ª2aûDù]„;Yt»\ôí¯¹[x’ìóù�ç]É}Wr½ÿ|É]”Ïg-´³Ú eW÷ ¶)6-r¼°CSÆjÊÈ išd ûDЇA½ÎœIqbJ#xÌ꺃 6k�àê#ª¢A„Sh°ëž&ÊŒt(QÊ%ìÌp%m�‡&]ÙcaSl=�XíòÀ¯èáü\P�1»MhŸ9£Mà¬ÌV®dDAí×aV×B�™[݈fJ�íP|8¯ Ö„AÛV^…ó¹f ÌH ín÷ÞÜ-Æ é"á€d>ÒzÏû¨nœ”ÇŠ¹ €Ø©ð‘>ä�bµ·–&ûÜÎâ¤2»Æv¹÷ÞÄKyϼ¤óöD:²¤œœ,AGm¯Õ\nzÈÇiÛÙã¼.uχYC¾6ìOMf“å3o¶rÅÜ$¨Ã5…µûœÂNH…T[XF64ÌT,Ñœ¬üËM0ëE)`#ý5¤XYƒ`ø×¤;º®%ã1ñUÙÙ¥m;ûš•R>QD ¢à�ØDìcp¿UÐ' ®&LEÐ/p�¦­m¦Üâœ%]ùöÊàì8fi„³r«S4Ïd 7y\È`ÞJâ�n•²åίŠIù R¥Æÿ3Uô~7+�ö€׸#�¯m� q¨BiDý¾€ÆÁÔˆ¸‹…i*¸L6ÿ9ÔÿmÎY&­áÀ§öiˆ…ýHE‚�=(K&úN!VÏö.K’e„LD•Ä•©{D 긪÷vEꦚdeÀàNÆŸûžeÐ(ÔMN9ßœRì½6þéÎÇ&3(åÖaÓÐäö/D¬ØUíz³<ß{ËŠè‰Y›Õȳ˜•¶‚V–ö¯)Â9·Z[±æ4^næÂ�ç5†Á¢!Já¾é?°ÿQá3ûeBo¨C¾µÁ‡M ¢ú’m<�.�vp�“´Á¤IYÓf­“¶Z¾Y_p§[ð=al-ÙYü}NcÍ™ËÎÉÅ‹4vfaÇÖvl¡©Á³'S†ÆùAÆ8Æ|Ò*uâ£{àè-¸ßŸ0%M0Á7%�¡õ˜<€ä·ÍÒ�¿ÿÿPK! Ñ�Ÿ¶'theme/theme/_rels/themeManager.xml.rels„�M Â0„÷‚wooÓº‘&݈ЭÔ„ä5 6?$Qìí ®,.‡a¾™i»—�Éc2Þ1hª:é•qšÁm¸ìŽ@RN‰Ù;d°`‚Žo7íg‘K(M&$R(.1˜r'J“œÐŠTù€®8£�Vä"£¦AÈ»ÐH÷u} ñ›|Å$½b{Õ–Pšÿ³ý8‰g/]þQAsÙ…(¢ÆÌà#›ªLÊ[ººÄßÿÿPK-!‚мú[Content_Types].xmlPK-!¥Ö§çÀ6 +_rels/.relsPK-!ky–ƒŠtheme/theme/themeManager.xmlPK-!–µ­â–PÑtheme/theme/theme1.xmlPK-! Ñ�Ÿ¶'› theme/theme/_rels/themeManager.xml.relsPK]– ] ÿÿÿÿ] v] ð8ð@ñÿÿÿ€€€÷ð’ðð0ð( ð ððB ðS ð¿Ëÿ ?ð+0PUV\j�±¶ ±_ i�&_ 3opxy�‚Š‹\ _ å+HOelí/Fñ] _ ÿ@€‹‹Xz‹‹] x@ÿÿUnknownÿÿÿÿÿÿÿÿÿÿÿÿG�‡* €ÿTimes New Roman5�€Symbol3.� ‡* €ÿArial7.�ï { @ŸCalibriY� CG TimesTimes New RomanA�ï ë BŸCambria Math"qˆðÐhŒëfŒëfeø�eø!ð  ´´��20Y Y 2ƒqðüýHP ðÿ$Päÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ/Fñ2!xx ÿÿ Adam Wallace Adam Wallaceþÿà…ŸòùOh«‘+'³Ù0|�˜¤°ÈÔàô  8 D P\dltäAdam Wallace Normal.dotmAdam Wallace1Microsoft Office Word@@nŠt†Ë@nŠt†ËeøþÿÕÍÕœ.“—+,ù®0ü hp�˜ ¨ °¸ÀÈ Ð ÝäºÚÁÏÍøY   Title þÿÿÿþÿÿÿ !"þÿÿÿ$%&'()*þÿÿÿýÿÿÿ-þÿÿÿþÿÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿRoot Entryÿÿÿÿÿÿÿÿ ÀF v¬t†Ë/€1Tableÿÿÿÿÿÿÿÿ íWordDocumentÿÿÿÿÿÿÿÿ4SummaryInformation(ÿÿÿÿDocumentSummaryInformation8ÿÿÿÿÿÿÿÿÿÿÿÿ#CompObjÿÿÿÿÿÿÿÿÿÿÿÿyÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿþÿ ÿÿÿÿ ÀF'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.8ô9²q